Innovating Works

IMPACT

Financiado
Improving DNA Analysis for Correct Healthcare
Over the past 10 years DNA sequencing has revolutionized how we apply genetics in personalized healthcare, diagnosis and drug development despite that the sequencing technology comes with numerous shortcomings. Samplix has develo... Over the past 10 years DNA sequencing has revolutionized how we apply genetics in personalized healthcare, diagnosis and drug development despite that the sequencing technology comes with numerous shortcomings. Samplix has developed a proprietary technology, Xdrop™, which addresses these shortcomings. Samplix’ technology encompasses state of the art microfluidics, molecular biology and bioinformatics. The Xdrop technology enables scientists and medical personnel to retrieve specific single DNA molecules from a minute amount of biological sample e.g. tumour biopsies, for subsequent DNA sequencing. At the core of the Xdrop technology is the generation of millions of droplets, each droplet constituting a reaction chamber for the sample preparation of single DNA molecules. This is opposed to today’s technology which is based on bulk preparation of sample material for DNA sequencing. Single molecule resolution is key to understanding the complexity of major diseases such as cancer, immunological diseases, mental disorders, etc. The proposed project addresses the need to qualify known market barriers and put measures in place to overcome such market barriers. Samplix has engaged a very experienced management team with an aggregated experience of >50 years in developing and selling products for DNA analysis. Samplix has already established: • 5 test site agreements with leading DNA institutions around the globe • Agreements with leading OEM providers on instrument and consumables • A patent estate of 5 patent families. • Freedom to operate in multibillion € market. At Samplix, we strive at 100 mUSD in revenue and profitability in year five after full commercial launch. To achieve such an ambitious goal, we plan to apply a razor/razor blade sales strategy by installing the instrument for free in return for a subscription to consumables Samplix raised 4,5 m€ in May 2018 which brings the total capital raised to 8 m€. A bigger financing round is planned for 2019. ver más
30/04/2021
SAMPLIX ApS
3M€
Duración del proyecto: 24 meses Fecha Inicio: 2019-04-12
Fecha Fin: 2021-04-30

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2021-04-30
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020: SME instrument
Cerrada hace 6 años
Presupuesto El presupuesto total del proyecto asciende a 3M€
Líder del proyecto
SAMPLIX ApS No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5